{"product_id":"in-vitro-diagnostics-market-by-offering-kits-software-technology-immunoassay-molecular-diagnostics-pcr-ngs-microarray-rapid-tests-biochemistry-application-infectious-diseases-oncology-diagnostic-approach-lab-poc-global-forecast-to-203","title":"In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 203","description":"\u003cp\u003eIn-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030\u003cbr\u003e\nIn-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030\u003c\/p\u003e\n\n\u003cp\u003eThe global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.\u003c\/p\u003e\n\n\u003cp\u003eThe growth of the global in vitro diagnostics market is mainly attributed to the rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities. Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics \u0026amp; proteomics offer significant growth opportunities for the players operating in this market.\u003c\/p\u003e\n\n\u003cp\u003eBased on offering, the reagents \u0026amp; kits segment is expected to grow with the fastest growth during the forecast period owing to its advantages as it can detect several markers simultaneously, which is useful for detecting complex diseases. Its technological superiority and the ability to facilitate chemical reactions further support the growth of this segment.\u003c\/p\u003e\n\n\u003cp\u003eBased on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. The largest share of the segment attributed to its improved specificity, cost-savings and enhanced throughput when automated, minimizing the false positive test results by targeting specific molecules, as well as improved diagnosis of infections such as orthopedic infections.\u003c\/p\u003e\n\n\u003cp\u003eBased on diagnostic approach, the laboratory testing segment is expected to account for the largest share of the market. Lab testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. Factors such as low costs of tests, highly sensitive analyzers, more accuracy and reliability, and accessibility \u0026amp; availability of multiple IVD tests support the largest share of the segment.\u003c\/p\u003e\n\n\u003cp\u003eBased on application, in 2023, the infectious diseases segment is expected to account for the largest share of the global in vitro diagnostics (IVD) market owing to the high prevalence of infectious diseases, government initiatives to promote awareness and testing, and emerging outbreaks of infectious diseases around the world.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the hospitals \u0026amp; clinics segment is expected to grow with the highest CAGR during the forecast period. Patient inflows at hospitals \u0026amp; clinics and subsequent increase in the volume of testing carried out in hospitals and clinics due to the outbreak of COVID-19 support the growth of this segment.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of the geographical scenario of the global in-vitro diagnostics (IVD) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East \u0026amp; Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD market, followed by Europe, Asia-Pacific, Latin America, and Middle East \u0026amp; Africa. The high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and presence of funding coupled with novel developments in diagnostic technologies support the large share of this market.\u003c\/p\u003e\n\n\u003cp\u003eThe key players operating in the global in-vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report:\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market Assessment—by Offering\u003c\/p\u003e\n\n\u003cp\u003eReagents \u0026amp; Kits\u003cbr\u003e\nInstruments\u003cbr\u003e\nSoftware \u0026amp; Services\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market Assessment—by Technology\u003c\/p\u003e\n\n\u003cp\u003eMolecular Diagnostics\u003cbr\u003e\nPolymerase Chain Reaction (PCR)\u003cbr\u003e\nHybridization\u003cbr\u003e\nIsothermal Nucleic Acid Amplification Technology\u003cbr\u003e\nDNA Sequencing \u0026amp; Next-generation Sequencing\u003cbr\u003e\nMicroarrays\u003cbr\u003e\nMass Spectrometry\u003cbr\u003e\nOther Molecular Diagnostic Technologies\u003c\/p\u003e\n\n\u003cp\u003e(Other Molecular Diagnostic Technologies majorly include electrophoresis, Ligase Chain Reaction (LCR), Northern Blot, and Southern Blot)\u003cbr\u003e\nPoint of Care (POC) Diagnostics\u003cbr\u003e\nLateral Flow Assays\/Rapid Tests\u003cbr\u003e\nPOC Molecular Diagnostics\u003cbr\u003e\nOther PoC Products\u003cbr\u003e\nImmunoassay\/Immunochemistry\u003cbr\u003e\nEnzyme-linked Immunosorbent Assays (ELISA)\u003cbr\u003e\nEnzyme-linked Immunospot Assays (ELISPOT)\u003cbr\u003e\nWestern Blotting\u003cbr\u003e\nRadioimmunoassay\u003cbr\u003e\nBiochemistry\/Clinical Chemistry\u003cbr\u003e\nMetabolic Panel\u003cbr\u003e\nElectrolyte Panel\u003cbr\u003e\nLiver Panel\u003cbr\u003e\nLipid Profile\u003cbr\u003e\nRenal Profile\u003cbr\u003e\nThyroid Function Panel\u003cbr\u003e\nWhole Blood Glucose Monitoring\u003cbr\u003e\nMicrobiology\u003cbr\u003e\nHematology\u003cbr\u003e\nCoagulation\/Hemostasis\u003cbr\u003e\nUrinalysis\u003cbr\u003e\nOther IVD Technologies\u003c\/p\u003e\n\n\u003cp\u003e(Other IVD technologies comprise anatomical pathology, histochemistry, and loop-mediated amplification).\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market Assessment—by Application\u003c\/p\u003e\n\n\u003cp\u003eInfectious Diseases\u003cbr\u003e\nCOVID-19 Testing\u003cbr\u003e\nSexually Transmitted Diseases (STD) Testing\u003cbr\u003e\nHealthcare-associated Infections (HAIs)\u003cbr\u003e\nHepatitis\u003cbr\u003e\nHIV\u003cbr\u003e\nTropical Diseases\u003cbr\u003e\nRespiratory Infections (Excluding Influenza)\u003cbr\u003e\nInfluenza\u003cbr\u003e\nOther Infectious Diseases\u003cbr\u003e\nOncology\u003cbr\u003e\nDiabetes\u003cbr\u003e\nCardiology\u003cbr\u003e\nNephrology\u003cbr\u003e\nAutoimmune Disorders\u003cbr\u003e\nOther Applications\u003c\/p\u003e\n\n\u003cp\u003e(Other applications comprise drugs of abuse tests, coagulation tests, neonatal testing, genetic testing, and neurological disorders testing).\u003c\/p\u003e\n\n\u003cp\u003e(Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market Assessment—by Diagnostic Approach\u003c\/p\u003e\n\n\u003cp\u003eLaboratory Testing\u003cbr\u003e\nOTC\/Self-testing\u003cbr\u003e\nPoint-of-Care Testing\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market Assessment—by End User\u003c\/p\u003e\n\n\u003cp\u003eDiagnostic Laboratories\u003cbr\u003e\nHospitals \u0026amp; Clinics\u003cbr\u003e\nHome Healthcare\u003cbr\u003e\nOther End Users\u003c\/p\u003e\n\n\u003cp\u003e(Other end users comprise nursing homes, academic \u0026amp; research institutes, ambulatory care centers, and transfusion laboratories.)\u003c\/p\u003e\n\n\u003cp\u003eGlobal In vitro Diagnostics Market Assessment—by Geography\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nU.K.\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nSwitzerland\u003cbr\u003e\nRest of Europe\u003cbr\u003e\nAsia-Pacific\u003cbr\u003e\nJapan\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of Latin America\u003cbr\u003e\nMiddle East\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nRest of Middle East\u003cbr\u003e\nAfrica\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Africa\u003c\/p\u003e\n\n\u003cp\u003eGlobal In Vitro Diagnostics Market - Report SummaryReport MetricsDetailsYears Considered2020 - 2030Base Year2022Forecast Period2023-2030Page Count526Units ReferencedValue (USD Million)Segments\/Key TopicsMarket by Offering, Technology, Application, Diagnostic Approach, and End UserRegions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East \u0026amp; Africa)Key Companies MentionedAbbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy)FAQs About the Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus of the global in vitro diagnostics market?\u003c\/p\u003e\n\n\u003cp\u003eThe global IVD market is segmented based on product \u0026amp; solution (reagents \u0026amp; kits, systems, and software \u0026amp; services) and a wide range of technologies (molecular diagnostics, point-of-care (PoC), immunoassay\/immunochemistry, biochemistry\/clinical chemistry, whole blood glucose monitoring, microbiology, hematology, coagulation\/hemostasis, urinalysis, and other IVD technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals \u0026amp; clinics, home healthcare, and other end users. The global IVD market studied in this report involves the value analysis of various segments and sub-segments of in vitro diagnostics at regional and country levels.\u003c\/p\u003e\n\n\u003cp\u003eWhat is the value of revenue generated from selling IVD solutions across the globe?\u003c\/p\u003e\n\n\u003cp\u003eThe global IVD market is projected to reach $130.1 billion by 2030, at a CAGR of 4.6% during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eWhich offering is estimated to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eThe reagents \u0026amp; kits segment is expected to account for the largest share of the global IVD market in 2023. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis support the largest share of the segment.\u003c\/p\u003e\n\n\u003cp\u003eWhich technology segment is projected to create more traction in the global IVD market?\u003c\/p\u003e\n\n\u003cp\u003eBased on the technology, the molecular diagnostics segment is projected to create more traction.\u003c\/p\u003e\n\n\u003cp\u003eWhich application segment is projected to create more traction in the global IVD market?\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the cardiology segment is projected to register the highest growth during the forecast period due to the growing cardiovascular disease (CVD) burden and increasing research on cardiac biomarkers.\u003c\/p\u003e\n\n\u003cp\u003eWhich end-user segment is projected to create more traction in the global IVD market?\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the hospitals \u0026amp; clinics segment is projected to register the highest growth during the forecast period due to increasing hospitalizations for treating diseases, the rising geriatric population, increasing healthcare access \u0026amp; expenditure, and the rising prevalence of healthcare-associated Infections (HAIs).\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global in vitro diagnostics market?\u003c\/p\u003e\n\n\u003cp\u003eRising prevalence of chronic and infectious diseases, growing awareness for early disease diagnosis, a shift in the focus from centralized to the point of care testing, and technological innovations. Further, emerging economies, the emergence of the COVID-19 pandemic, and advances in genomics and proteomics offer significant growth opportunities for the players operating in this market.\u003c\/p\u003e\n\n\u003cp\u003eWho are the major players operating in the global IVD market?\u003c\/p\u003e\n\n\u003cp\u003eThe key players operating in the global IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).\u003c\/p\u003e\n\n\u003cp\u003eWhich regions\/countries will likely offer significant growth opportunities for the vendors in this market during the analysis period?\u003c\/p\u003e\n\n\u003cp\u003eThe emerging countries from Asia and Latin America are projected to offer significant growth opportunities for the vendors in this market due to rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, growing infectious diseases, and growing accessibility to healthcare services \u0026amp; advanced products.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ - \/ MCW16230047","offer_id":47647036277042,"sku":null,"price":5010.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/in-vitro-diagnostics-market-by-offering-kits-software-technology-immunoassay-molecular-diagnostics-pcr-ngs-microarray-rapid-tests-biochemistry-application-infectious-diseases-oncology-diagnostic-approach-lab-poc-global-forecast-to-203","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}